Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Sep

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Cleveland Clinic President Discusses AI Summit for Health-Care Professionals

AI’s Evolving Role in Clinical Care Enterprise-Wide

Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer

Cancer Statistics 2026: What Every Medical Oncologist Should Know

Short-Course SBRT Better Preserves Physical Function Before Pancreatic Cancer Surgery